Thalidomide Celgene (previously Thalidomide Pharmion)-H-C-PSUSA-00002919-201510: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Fortschrittliche pharmazeutische Formulierung für gezielte therapeutische Intervention.

Dosierung

Stärke

Thalidomide Celgene (previously Thalidomide Pharmion)-H-C-PSUSA-00002919-201510: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Packungsgröße

Thalidomide Celgene (previously Thalidomide Pharmion)-H-C-PSUSA-00002919-201510: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Form

Thalidomide Celgene (previously Thalidomide Pharmion)-H-C-PSUSA-00002919-201510: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Quelle

European Medicines Agency

Quelle anzeigen

Sicherheitsprofil

Kontraindikationen

Thalidomide Celgene (previously Thalidomide Pharmion)-H-C-PSUSA-00002919-201510: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Nebenwirkungen

Thalidomide Celgene (previously Thalidomide Pharmion)-H-C-PSUSA-00002919-201510: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation